Ionis Pharmaceuticals

News

West Chester - Circa November 2020: AstraZeneca plant. AstraZeneca has been working on a vaccine for the Coronavirus, COVID and COVID-19.

AZ gets closer to Ionis, licensing amyloidosis drug in $3.6b...

AstraZeneca has snapped up another Ionis-discovered drug for its pipeline, this time phase 3 candidate eplontersen for the disease transthyretin amyloidosis (ATTR).

News

The critical role of the generics sector during the pandemic

Could safety scupper Ionis, Pfizer's cholesterol drug vupano...

Ionis has reported phase 2b trial data for its Pfizer-partnered antisense drug vupanorsen for cholesterol lowering that showed it met its main efficacy targets, but raised a few safety conc

News

NICE relents and okays Akcea’s rare disease drug Waylivra fo...

Patients with the rare disease familial chylomicronemia syndrome (FCS) will be able to access treatment with Akcea’s Waylivra via the NHS, after a U-turn by NICE.

News

GSK takes option to license hepatitis B RNA drugs from Ionis

GlaxoSmithKline has taken an option to license Ionis’ antisense medicines for people with chronic hepatitis B virus infection after supportive phase 2 trial results.

News

Ionis' FCS drug approved in EU, launch due in Germany

Ionis Pharmaceuticals’ RNA-targeted drug Waylivra has been conditionally approved in Europe for the devastating ultra-rare disease Familial Chylomicronemia Syndrome (FCS).

News

Ionis and Roche to develop RNAi AMD drug in $760m deal

Ionis and Roche have struck a deal worth up to $760 million (£575 million) to develop a drug to treat advanced age-related macular degeneration (AMD), a leading cause of blindness.

AZ gets closer to Ionis, licensing amyloidosis drug in $3.6b...

Could safety scupper Ionis, Pfizer's cholesterol drug vupano...

NICE relents and okays Akcea’s rare disease drug Waylivra fo...

GSK takes option to license hepatitis B RNA drugs from Ionis

Ionis' FCS drug approved in EU, launch due in Germany

Ionis and Roche to develop RNAi AMD drug in $760m deal

Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer

Discover a new era of healthcare panel engagement: Grounded ...

Ionis Pharmaceuticals

Editor's Picks